Leukocyte adhesion deficiency' (LAD) is an inherited immunodeficiency disease that is characterized by the deficient expression of the leukocyte adhesion glycoproteins lymphocyte function-associated antigen-i (LFA-1), Mac-i, and pi50,95. 
Introduction
The leukocyte integrins, lymphocyte function-associated antigen-1 (LFA-1),' Mac-1, and p150,95 are heterodimers consisting of a unique a subunit noncovalently associated with a 1. Abbreviations used in this paper: CMV, cytomegalovirus; LAD, leukocyte adhesion deficiency; LFA-1, lymphocyte function-associated antigen- 1. common (3 subunit (1) . The importance of this family of glycoproteins in adhesion-related functions has been emphasized by the discovery of a rare human genetic disease called leukocyte adhesion deficiency (LAD; reviewed extensively in reference 2). Patients with LAD are deficient in their cell surface expression of LFA-1, Mac-1, and p150,95. The characteristic features of LAD are recurrent life-threatening bacterial and fungal infections, gingivitis, severely impaired pus formation, and chronic leukocytosis. Lymphocytes, monocytes, and granulocytes from patients with LAD show a wide range of defects in adhesion-related functions such as adhesion to endothelial cells, cell migration, cell-mediated cytolysis, and antigen presentation (2, 3) . On the basis of quantitative differences in expression of the LFA-1 glycoprotein family, severe (expressing < 1% of normal levels of a(3 complexes) and moderate (expressing 3-10% of normal levels) deficiency phenotypes have been defined (4) . The degree of glycoprotein deficiency directly relates to the severity of the clinical complications. Moderately deficient patients, although often severely afflicted, can live to adulthood; however, patients suffering from the severe form of the disease usually die early in childhood from overwhelming infections.
Several lines of evidence have suggested that the defect in LAD is due to the common # subunit. In every patient studied to date, expression of all three leukocyte integrins has been found to be deficient. Studies using mouse X human lymphocyte hybrids constructed from an LFA-1 + mouse T lymphoma and the lymphocytes of one patient demonstrated that surface expression of the human LFA-1 a subunit but not the A subunit from LAD patient cells could be rescued by the formation of interspecies a(3 complexes, indicating that the a subunit from this patient was competent for surface expression but that the ( subunit was not (5) . Biosynthetic studies ofthe a and A subunits of the leukocyte integrins indicate that they are synthesized as precursors containing high-mannose N-linked oligosaccharides (1, 6) . Association of the a subunit precursor with the (3 subunit precursor is necessary for additional carbohydrate processing and transport to the cell surface. Association with an a subunit was not detectable in any of the LAD patients who synthesize a A subunit precursor (7) (8) (9) . After the isolation of cDNA clones encoding the (3 subunit of the leukocyte integrins (10, I 1) it was demonstrated that heterogeneous mutations in the common d subunit give rise to LAD (8, 12) . To date, five distinct classes of mutations have been identified. Two classes of mutations affect the gross structure of the ( subunit giving rise to either aberrantly large or small ( subunit (8) . One class of mutation results in no detectable mRNA or protein precursor, while a fourth class of mutation is characterized by the synthesis of trace amounts of ( subunit precursor and low levels of message (8, 12) . A fifth class of mutation results in synthesis of a (3 subunit that appears normal by SDS-PAGE, but fails to associate with the a subunit (8, 9, 12, 13) . This class of mutation could be due to point mutations in a or (3, or could affect a third protein required for their assembly. We have recently studied the genetic basis for the defect in four related patients of the moderate deficiency phenotype who synthesize an aberrantly small form of the common (3 subunit (14) . Aberrant splicing in 95% ofthe mRNA caused by a mutation in a 5' splice site resulted in a 30 amino acid deletion in a highly conserved region of the (3 FACS analysis. Expression of LFA-l was quantitated 6 wk posttransfection by indirect immunofluorescence (23) . MAb (50 1l of a 1: 100 dilution ofascites) was incubated with 50 Ml ofcells( (I07 cells/ml) for 30 min on ice. The cells were washed twice with PBS/0.5% BSA, then resuspended in 50 Ml of a 1: 10 dilution of FITC-conjugated goat anti-mouse IgG (Zymed, San Francisco, CA) and incubated on ice for a further 30 min. After washing twice with PBS/0.5% BSA, cells were fixed with 1% paraformaldehyde in PBS. The fluorescence of labeled cells was analyzed on an Epics V flow cytometer.
Cell labeling and immunoprecipitation. EBV-transformed B cell lines in log phase of growth were washed three times in PBS and resuspended to I07 cells/ml. 1 mCi of Nal25I was added to 2 ml of cells and the entire mixture transferred to lodo-gen (Pierce Chemical Co., Rockford, IL)-coated glass vials for 10 min with intermittent agitation (24) . Free '25I was quenched by the addition of RPMI/10% FCS and the cells were washed three times in the same medium. The cell pellets were lysed in 1 ml of 1% Triton X-100, 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% hemoglobin, 1 mM iodoacetamide, 1 mM PMSF, 0.24 trypsin inhibitory units/ml aprotinin, and 0.025% NaN3 for 45 min at 4°C. Nuclei were pelleted at 12,000 g for 15 min at 4°C and the lysates were precleared overnight with 100 Ml packed bovine Ig coupled to Sepharose. Immunoprecipitation was carried out by incubating equal amounts of lysate with 20 Ml of either anti-,B subunit MAb (TS1/18), anti-LFA-l a subunit MAb (TS1/22), anti-ICAM-1 MAb (RRl/1), or bovine Ig (control) coupled to Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) for 2 h at 4°C. The immunoprecipitates were washed three times with 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100, twice with 25 mM Tris-HCl, pH 8.0, and 150 mM NaCl, and once with 50 mM Tris-HCI, pH 8.0. Immunoprecipitates were subjected to SDS-PAGE under reducing conditions (25) .
Northern analysis. Total mRNA was isolated from EBV-transformed cell lines using guanidinium isothiocyanate and centrifugation in CsCl gradients (26) . Northern blotting was carried out as described (10, 27 Purification ofICAM-1. ICAM-l was purified by affinity chromatography on RRl/l-Sepharose from lysates of hairy cell spleens (29) . Briefly, hairy cell spleens (30 g) were lysed in 650 ml of 1% Triton X-100, 10 mM Tris-HCI, pH 8.0, 150 mM NaCI, 5 mM iodoacetamide, 0.5 mM PMSF, 1 mM diisopropylfluorophosphate, 0.24 trypsin inhibitory units/ml aprotinin, and 0.025% NaN3 for 45 min at 4°C.
Nuclei and aggregates were removed by centrifugation for 30 min at 3,500 rpm followed by 90 min at 10,000 rpm and filtration through filter paper (# 1; Whatman Laboratory Products Inc., Clifton, NJ). The lysate was precleared with 5 ml packed bovine Ig-Sepharose for 2 h at 40C, then loaded onto the RR1/I column and run through at a flow rate of 0.5 ml/min. The column was then washed as previously described (30) and eluted with 50 mM triethylamine, pH 12.5, 150 mM NaCl, and 1% octylglucoside. Fractions were neutralized immediately with 0.2 vol of 1 M Tris-HCl, pH 6.7/1% octylglucoside, snap-frozen in liquid nitrogen, and stored at -70'C.
Binding of transfectants to purified, plastic-bound ICAM-1. Stable transfectants were tested for their ability to bind to purified ICAM-1 coated onto plastic (31) (19) and its ability to be expressed was initially demonstrated in COS cells by cotransfection with the LFA-l a subunit (not shown). We then constructed the vector pEBCB 1 (Fig. 1) by subcloning a fragment of CDM8 containing the (3 subunit cDNA as well as the Ml 3 origin, CMV promoter, and polyadenylation signals into the polycloning site of the EBV-based vector p205118a (see Methods). EBV-transformed B lymphoblastoid cell lines from four unrelated patients with different classes of mutations and phenotypes were used for transfection. Cell lines derived from patients 1, 2, and 15 produced normal levels of (3 subunit mRNA and protein precursor; the patient 1 (3 subunit precursor was variously reported as aberrantly large (8; Wardlaw, A. J., unpublished observations) or normal in size (13 (8) . EBV lines from patients 2 and 12 lacked any detectable cell surface LFA-1 a or (3 subunits, and the line from patient 15 expressed small amounts (Fig. 2) in agreement with previous typing as severe or moderate deficiency, respectively (4, 17, 18) . Patient 1 appeared to express small amounts of surface LFA-I (Fig. 2) p 150,95 on neutrophils (4, 18) . Cells resistant to hygromycin B were selected 48 h posttransfection. 2-3 wk later a pure population of hygromycin-resistant cells expressing LFA-l was obtained. Cells were tested for expression of LFA-1 by flow cytometry using both anti-LFA-1 a (TS 1/22) and anti-,B subunit (TS 1/18)-specific MAbs (Fig. 2) . After transfection with the ,B subunit cDNA, expression of both the a and , subunits of LFA-l was recovered in all four LAD patient cell lines (Fig. 2) . The level of expression was comparable to that in the C03 line, which is the most appropriate control since it was EBVtransformed from a healthy individual in parallel to the patient lines. However, JY cells, a high LFA-l-expressing cell line, expressed more LFA-1 than did the transfectants.
SDS-PAGE analysis oftransfectants. To confirm that fully processed LFA-1 a and fl subunits were being expressed on the cell surface of the stable transfectants, three of the four transfected patient cell lines were analyzed by surface labeling and immunoprecipitation (Fig. 3) . LFA-1+ LAD transfected cells derived from patients 2, 12, and 15 expressed normal-sized LFA-1 a and fl chains as demonstrated by immunoprecipitation with both an anti-LFA-l a subunit MAb (Fig. 3, C , E, and G; lane 2) and an anti-,8 subunit MAb (Fig. 3, C , E, and G; lane 3) and comparison with LFA-I immunoprecipitated from JY cells (Fig. 3 A, lanes 2 and 3) . All nontransfected patient cells were deficient in cell surface expression of mature LFA-1 (Fig. 3 , B, D, and F; lanes 2 and 3) but had normal levels of expression of ICAM-1, which is a 97,000-D glycoprotein (Fig.  3 , B, D, and F; lane 4). A low but discernible amount of iodinated LFA-I a precursor (1 70,000-D), which was presumably labeled after some cell lysis during the labeling procedure, was detected in the nontransfected cell lines by immunoprecipitation with an anti-LFA-1 a subunit-specific MAb (Fig. 3 was probed with a nick-translated cDNA probe from the 5' end of the ,3 subunit (Fig. 4) . With the exception of patient 12, who produced no detectable message (Fig. 4, lane 6 ) (8), nontransfected LAD patient cells (Fig. 4, lanes 2, 4, and 8 ) expressed relatively normal levels of A subunit message when compared with healthy control cells (C03; Fig. 4, lane 1) . In the transfected cell lines (Fig. 4, lanes 3, 5, 7 , and 9), a transcript derived from the 1 subunit expression vector was present that was larger than the endogenous A subunit mRNA. The predicted size of 3 subunit message transcribed in pEBCBl was -3.4
kb, which is slightly larger than the single 13 subunit mRNA species of 3 kb inherent in C03 and nontransfected LAD patient cells. Interestingly, different levels of expression of the exogenous , subunit mRNA were apparent. Transfected cells from patient 12 (Fig. 4, lane 7) expressed significantly higher amounts of 13 subunit message than did any of the other transfected cells. Patient 15 expressed the lowest amount of 13 message (Fig. 4, lane 5) , while patients 1 and 2 expressed intermediate levels (Fig. 4, lanes 3 and 9) . Transfected LAD patient cells can homotypically aggregate. As a means of testing whether functional capability had been restored in the LFA-1-expressing LAD patient cell lines, PMA-stimulated aggregation of the transfectants was examined (Table I; Fig. 5 ). Stable LFA-1 + LAD transfectants could form aggregates both in the presence and absence of PMA; however, PMA enhanced the rate and magnitude of the response (Table I) . This response could be inhibited by the addition of anti-LFA-1 MAb (Table I; Fig. 5) . The TS2/6 LFA-1 MAb was not as efficient in inhibiting a strong aggregation response, but could totally inhibit weaker responses. The magnitude of the response of the LAD transfectants compared favorably with the expression of LFA-1 on their cell surface. Transfected LAD EBV-transformed cells from patient 2, the highest LFA-1-expressing transfectant, aggregated strongly in the presence of PMA and when PMA was omitted from the media (Table I ; Fig. 5 ). The other cell lines aggregated well in the presence of PMA but to a lesser degree. In contrast, there was no aggregation of the nontransfected LFA-1-EBV-transformed cells from the three severely deficient patients or the one moderately deficient patient after 2 h incubation at 37°C (Table I) .
LFA-J-expressing LAD patient cells bind ICAM-I. Recently it has been demonstrated that LFA-1-expressing cell lines can bind to purified ICAM-1 absorbed to polystyrene microtiter plates (31) . We adopted this approach to examine the ability of two of the stable LFA-1+ LAD transfectants to function in binding to ICAM-1 and to investigate whether binding could be upregulated by phorbol esters (Fig. 6 ). In the absence of PMA, LFA-1 + transfectants derived from patients 2 and 12 could bind to purified ICAM-1, and this binding was totally abrogated by anti-ICAM-1 MAb (Fig. 6, A and B) and anti-LFA-1 MAb (not shown). As has been shown previously with JY cells (31) , PMA could dramatically increase adhesion of the transfectants to ICAM-1 (Fig. 6 ). This interaction could also be inhibited by anti-ICAM-1 MAb (Fig. 6 ) and anti-LFA-1 MAb (not shown). In contrast, nontransfected LAD patient cell lines showed no binding to ICAM-1 above back- ground levels of adhesion in either the presence or absence of PMA (Fig. 6 ).
Discussion
In this study we have demonstrated that functional-LFA-I can be reconstituted in cell lines derived from a number ofpatients with LAD, a disease characterized by deficient expression of the leukocyte adhesion glycoproteins (2, 3, 8) . In all patient cell lines studied, LFA-1 expression and function could be restored upon transfection with the leukocyte integrin 13 subunit, and Northern blotting confirmed that exogenous 13 subunit mRNA was being expressed. LAD patient cell lines characterized as having different classes of mutations and different deficiency phenotypes were used in these studies. Although evidence already implies that LAD is secondary to mutations in the common 13 subunit (5, 8, 14) , it is conceivable that patients who synthesize the 13 subunit which appears grossly normal by SDS-PAGE may have point mutations in the a subunits rather than the 13 stably transfected with the (3 subunit) aggregated to a similar degree as control cells but faster and to a greater degree than those expressing lower levels. Cell lines expressing lower levels of LFA-I were not as effective as JY or C03 in the homotypic aggregation assay. Transfected cell lines derived from all four patients were able to bind to the LFA-1 counterreceptor, ICAM-1, although those expressing lower levels ofLFA-I were not as efficient ( Fig. 6 ; data not shown). In addition, the avidity of LFA-l for ICAM-I could be increased in all four transfected cell lines with phorbol esters, indicating that intracellular signaling pathways are intact in these cells (31) . The studies presented here, which demonstrate that LFA-1 expression and function can be restored in LAD patient cell lines with the leukocyte integrin # subunit cDNA, indicate that this genetic disease is likely to be a good candidate for gene therapy. We anticipate that even low levels of expression of this family of glycoproteins should greatly reduce the clinical complications associated with LAD in patients of the severe phenotype, as moderately deficient LAD patients who express only 3-10% of normal levels of LFA-1, Mac-l, and p150,95 have a significantly better prognosis than severely deficient patients who express < I% of normal levels (2, 3) . In addition, heterozygotes who have as low as 50% expression have normal function.
The ability of EBV-transformed B lymphoblastoid cell lines derived from patients with LAD to have LFA-1 expression and function restored upon stable transfection with the ,3 subunit cDNA now makes for an extremely useful model to study mutants of the (3 subunit gene. This system would be superior to using foreign recipient cells which may lack the appropriate phosphorylation machinery or cytoskeletal components necessary for precisely tuned function. Thus, stable expression of subunit mutants in B lymphoblastoid cell lines would enable not only the determination ofthe precise contact sites between the, a and (3 subunits and regions in the ( subunit which contribute to ligand binding specificity, but regions responsible for PMA-stimulated adhesion and contact sites for cytoskeletal proteins.
